Role of gemifloxacin in community-acquired pneumonia

References

• Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance. Am. J. Public Health90, 223–229 (2000).
   PubMed Web of Science ®Google Scholar
• Marrie TJ. Community-acquired pneumonia. Clin. Infect. Dis.18, 501–513 (1994).
   PubMed Web of Science ®Google Scholar
• Ruiz M, Ewig S, Marcos MA et al. Etiology of community acquired pneumonia: impact of age, comorbidity, and severity. Am. J. Respir. Crit. Care Med.160, 397–405 (1999).
   PubMed Web of Science ®Google Scholar
• British Thoracic Society. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax56(Suppl. 4), IV1–IV64 (2001).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Marston BJ, Plouffe JF, File TM et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch. Intern. Med.157, 1709–1718 (1997).
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther.20(4), 820–837 (1998).
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL. Economic burden of pneumonia in an employed population. Arch. Intern. Med.161(22), 2725–2731 (2001).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Garau J, Blasi F et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest125, 1888–1901 (2004).
   PubMed Web of Science ®Google Scholar
• Echols RM, Tillotson GS, Tosiello R, Song J. Clinical trial design for mild to moderate community acquired pneumonia – an industry perspective. Clin. Infect. Dis. (2008) (In Press).
   Google Scholar
• Echols RM, Anderson A. Comparison of etiology of community-acquired pneumonia by Fine class. Presented at: 43rd Annual Meeting of the IDSA, San Diego, CA, USA (2003) (Abstract 519).
   Google Scholar
• Felmingham D, Grüneberg RN; The Alexander Project Group. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother.45, 191–203 (2000).
   PubMed Web of Science ®Google Scholar
• Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother.50(Suppl. S1), 25–37 (2002).
   PubMed Web of Science ®Google Scholar
• Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999–2003). Int. J. Antimicrob. Agents26(6), 479–485 (2005).
   PubMed Web of Science ®Google Scholar
• Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother.52, 944–952 (2003).
   PubMed Web of Science ®Google Scholar
• Low DE. Resistance trends in Haemophilus influenzae (PROTEKT years 1–3 [1999–2002]). J. Chemother.16(Suppl. 6), 49–61 (2004).
   PubMed Web of Science ®Google Scholar
• Jorgensen JH. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin. Infect. Dis.14(5), 1119–1123 (1992).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN; The Alexander Project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother.52(2), 229–246 (2003).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ; CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother.47(6), 1875–1881 (2003).
   PubMed Web of Science ®Google Scholar
• Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY antimicrobial surveillance program. Clin. Microbiol. Infect.10, 645–651 (2003).
   Web of Science ®Google Scholar
• Calca-Mercado JJ, Castillo G, Lopez-Vidal Y. Actividad de las fluoroquinolonas en aislamentos clincos de Streptococcus pneumoniae con diferente susceptibilidad a la penicilina: studio epidemilogico en cinco ciudades de la Republica Mexicana. Gac. Med. Mex.141,253–258 (2005).
   Google Scholar
• Draghi DC, Jones ME, Sahm DF, Tillotson GS. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003–2004). Int. J. Antimicrob. Agents28(6), 525–531 (2006).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA298(15), 1772–1778 (2007).
   PubMed Web of Science ®Google Scholar
• Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis.31, 1008–1011 (2000).
   PubMed Web of Science ®Google Scholar
• Metlay JP, Kopoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. J. Am. Med. Assoc.278, 1440–1445 (1997).
   PubMed Web of Science ®Google Scholar
• Garau J. The clinical impact of macrolide resistance in pneumococcal respiratory infections. Int. J. Antimicrob. Agents18(Suppl. 1), 33–38 (2001).
   Google Scholar
• Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis.35(5), 556–564 (2002).
   PubMed Web of Science ®Google Scholar
• Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams. J. Antimicrob. Chemother.51, 691–696 (2003).
   PubMed Web of Science ®Google Scholar
• Schrag SJ, Peña C, Fernández J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA286(1), 49–56 (2001).
   PubMed Web of Science ®Google Scholar
• File T. Clinical efficacy of newer agents in short duration therapy for community-acquired pneumonia. Clin. Infect. Dis.39, S159–S164 (2004).
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy and safety. Pharmacotherapy25(5), 717–740 (2005).
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis.37, 752–760 (2003).
   PubMed Web of Science ®Google Scholar
• Morrissey I, Tillotson G. Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. J. Antimicrob. Chemother.53, 144–148 (2004).
   PubMed Web of Science ®Google Scholar
• Morrissey I, Clark S, Mathias I. The bactericidal activity of gemifloxacin (SB-265805). J. Med. Microbiol.49(9), 841–844 (2000).
   PubMed Web of Science ®Google Scholar
• Garcia-Olmos M, Parra A, Garcia-Calvo G et al. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility. Int. J. Antimicrob. Agents21(6), 568–573 (2003).
   PubMed Web of Science ®Google Scholar
• Azoulay-Dupuis E, Bédos JP, Mohler J et al. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob. Agents Chemother.49, 1046–1054 (2006).
   Web of Science ®Google Scholar
• Bast DJ, Dresser L, Duncan CL et al. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice. J. Chemother.18(6), 634–640 (2006).
   PubMed Web of Science ®Google Scholar
• Dresser LD, deAzavedo JCS, Duncan CL, Low DE, Bast DJ. Short-course therapy of gemifloxacin versus moxifloxacin against murine pneumococcal pneumonia caused by a single-step ParC mutant. Presented at: 45th Annual Meeting of IDSA, San Diego, CA, USA (2007) (Abstract 491).
   Google Scholar
• Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr. Opin. Pharmacol.1, 459–463 (2001).
   PubMedGoogle Scholar
• Saravolatz L, Manzor O, Pawlak J, Belian B. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. Int. J. Antimicrob. Agents26(1), 81–84 (2005).
   PubMed Web of Science ®Google Scholar
• Ball P, File TM, Twynholm M et al. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int. J. Antimicrob. Agents18, 19–27 (2001).
   PubMed Web of Science ®Google Scholar
• Lode H, File TM Jr, Mandell L, Ball P, Pypstra R, Thomas M; 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther.24(11), 1915–1936 (2002).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Schlemmer B, Garau J et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother.48, 67–74 (2001).
   PubMed Web of Science ®Google Scholar
• Léophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med.98(8), 708–720 (2004).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J. Antimicrob. Chemother.60(1), 112–120 (2007).
   PubMed Web of Science ®Google Scholar
• Gemifloxacin package insert, 2007 (Factive). Oscient Pharmaceuticals, Waltham, MA, USA.
   Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis.37(11), 1405–1433 (2003).
   PubMed Web of Science ®Google Scholar
• Morrissey I, File TM Jr, Mandell LA, Tillotson G. Patient risk factors in community-acquired pneumonia infections outcome following treatment with gemifloxacin. Presented at: 3rd ISC DMS, Montreal, Canada, September, 2005 (Abstract 19).
   Google Scholar
• Morrissey I, File TM Jr, Mandell LA, Tillotson G. Cardio–pulmonary medical history and the effect on clinical outcome of community-acquired pneumonia infections treated with gemifloxacin. Presented at: 3rd ISC DMS, Montreal, Canada, September, 2005 (Abstract 20).
   Google Scholar
• Bhavnani SM, Ambrose PG. Cost–effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn. Microbiol. Infect. Dis.60(1), 59–64 (2008).
   PubMed Web of Science ®Google Scholar